Cipla Cancer Drug Recall Impacts US Market Cipla Limited has initiated a significant recall of over 400 cartons of Nilotinib Capsules in the United States following regulatory action by the US Food and Drug Administration. The recall stems from manufacturing specification failures identified during quality control processes. Nilotinib is a critical tyrosine kinase inhibitor used primarily in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors, making this recall particularly concerning for patient care continuity. The USFDA classification and scope of this recall underscores the importance of stringent pharmaceutical manufacturing standards. Cipla, one of India's largest pharmaceutical companies with substantial US market presence, faces potential reputational and financial implications from this quality control issue.
